| Drug ID: | Drug96 |
|---|---|
| Drug Name: | Nifuroxazide |
| CID: | 5337997 |
| DrugBank ID: | DB13855 |
| Modality: | Small Molecule |
| Groups: | NULL |
| US Approved: | NULL |
| Other Approved: | NULL |
| Identifier: | NCT05988528 |
| Molecular Formula: | C12H9N3O5 |
| Molecular Weight: | 275.22 g/mol |
| Isomeric SMILES: | C1=CC(=CC=C1C(=O)N/N=C/C2=CC=C(O2)[N+](=O)[O-])O |
| Synonyms: | Nifuroxazide; 965-52-6; Nifuroxazid; Dicoferin; Nifuroxazida; Diarlidan; Nifuroxazidum; Ercefurol; Nifuroxazidum [INN-Latin]; Nifuroxazida [INN-Spanish] |
| Phase 0: | 0 |
| Phase 1: | 0 |
| Phase 2: | 0 |
| Phase 3: | 0 |
| Phase 4: | 0 |
| Description: | NULL |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt811 | 5337997 | Nifuroxazide | 836 | CASP3 | Rattus norvegicus (Norway rat) | 29606028 | Nifuroxazide inhibits the reaction [streptozocin results in increased activity of CASP3 protein]|nifuroxazide inhibits the reaction [streptozocin results in increased cleavage of CASP3 protein] |
| dt812 | 5337997 | Nifuroxazide | 841 | CASP8 | Rattus norvegicus (Norway rat) | 29606028 | Nifuroxazide inhibits the reaction [streptozocin results in increased activity of CASP8 protein] |
| dt813 | 5337997 | Nifuroxazide | 842 | CASP9 | Rattus norvegicus (Norway rat) | 29606028 | Nifuroxazide inhibits the reaction [streptozocin results in increased activity of CASP9 protein] |
| dt814 | 5337997 | Nifuroxazide | 6361 | CCL17 | Homo sapiens (human) | 28949055 | Nifuroxazide inhibits the reaction [[IFNG protein co-treated with TNF protein] results in increased expression of CCL17 mrna] |
| dt815 | 5337997 | Nifuroxazide | 6367 | CCL22 | Homo sapiens (human) | 28949055 | Nifuroxazide inhibits the reaction [[IFNG protein co-treated with TNF protein] results in increased expression of CCL22 mrna] |
| dt816 | 5337997 | Nifuroxazide | 968 | CD68 | Rattus norvegicus (Norway rat) | 29291386 | Nifuroxazide inhibits the reaction [streptozocin results in increased expression of CD68 protein] |
| dt817 | 5337997 | Nifuroxazide | 3458 | IFNG | Homo sapiens (human) | 28949055 | Nifuroxazide inhibits the reaction [[IFNG protein co-treated with TNF protein] results in increased expression of CCL17 mrna]|nifuroxazide inhibits the reaction [[IFNG protein co-treated with TNF protein] results in increased expression of CCL22 mrna] |
| dt818 | 5337997 | Nifuroxazide | 3606 | IL18 | Rattus norvegicus (Norway rat) | 29291386 | Nifuroxazide inhibits the reaction [streptozocin results in increased expression of IL18 mrna] |
| dt819 | 5337997 | Nifuroxazide | 3569 | IL6 | Homo sapiens (human) | 31748929 | Nifuroxazide inhibits the reaction [benzo(a)pyrene results in increased secretion of IL6 protein] |
| dt820 | 5337997 | Nifuroxazide | 5970 | RELA | Rattus norvegicus (Norway rat) | 29606028 | Nifuroxazide inhibits the reaction [streptozocin results in increased localization of RELA protein] |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT05988528 | Clinical Study to Evaluate the Possible Efficacy of Nifuroxazide in Patient With Ulcerative Colitis | PHASE2|PHASE3 | RECRUITING | Mostafa Bahaa | Inflammatory Bowel Diseases | DRUG: Mesalamine|DRUG: Nifuroxazide | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| No data available | |||||
A Randomized Controlled Pilot Study Evaluating the Safety and Efficacy of Nifur…
PMID: 40620467
Year: 2025
Relationship Type:
Treatment
Score: 10.0
BACKGROUND: The therapeutic potential of nifuroxazide in colitis has been explored in several experimental studies of ulcerative colitis (UC). AIM: T…
Pharmacological updates of nifuroxazide: Promising preclinical effects and the …
PMID: 37192715
Year: 2023
Relationship Type:
Mechanism
Score: 9.5
Nifuroxazide (NFX) is a safe nitrofuran antibacterial drug used clinically to treat acute diarrhea and infectious traveler diarrhea or colitis. Recen…
Regulation of IL-6/STAT-3/Wnt axis by nifuroxazide dampens colon ulcer in aceti…
PMID: 33794250
Year: 2021
Relationship Type:
Treatment
Score: 9.5
AIM: Ulcerative colitis (UC) is a common intestinal problem characterized by the diffusion of colon inflammation and immunity dysregulation. Nifuroxa…
The interplay of the inhibitory effect of nifuroxazide on NF-κB/STAT3 signaling…
PMID: 32526270
Year: 2020
Relationship Type:
Treatment
Score: 9.5
Ulcerative colitis (UC) is a disease of increased worldwide prevalence. UC progression is associated with serious complications that leave the patien…